merous subspecialists, all working towards the assessment of the functional state of the heart. These specialists include: electrophysiologists, ultra-sonographers, nuclear cardiologists, catheterization and angioplasty experts, coronary circulation and muscle mass assessors. All of this expertise is brought to bear on the clinical problem. Consider, then, the pligh~ofthe pathologist who is expected to interpret the biopsy or autopsy findings in a dynamic manner.
Unless the pathologist is able to utilize the in vivo findings in a meaningful way, there is the danger of developing a "credibility gap." This makes it necessary for the pathologist to be familiar with the methods and terms used by clinical investigators.
GROSS ANATOMY OF THE HEART
T~e left ven~ri cl e is the powerhouse of the heart.
axII?al, efficient work is totally dependent on the integrity of the muscle. From the fixed base of the heart to the apex, the left ventricle is a cone. This geometry requires a special type of contraction if th.eblood volume is to be fully ejected into the aorta WIth each systole. The apex is pulled up towards the base as the spiral muscles twist the chamber in a wringing motion. To achieve this effect there is a unique .interdigitation of the spiral muscles. Thus, t~e major e~ergy created and expended is in the cIrcu!UferentI~1 zone between the base and apex. PreVIOUS studies have demonstrated that oxidative phosphorylation in this zone is greater than at the base or apex. Biochemically, the heart is not a static organ (8, 20, 26) .
C~reful ultrasound studies can identify those areas I~th~heart which do not contract effectively (dyskme~Ia) or do not contract at all (akinesia). The pathologist needs to examine these areas in an attempt to explain the functional abnormalities. In ad~itio~to searching for myofiber pathology, exammanon of the extracellular matrix or interstitial tissues is also required. Collagen fibers are the major structural elements in the interstitium. They are the 481 INTRODUCTION Just 50 yr ago, a prominent academic cardiologist stated that open-heart surgery was a dream. Any procedure which created a by-pass ofthe circulation, stopped the heart, performed surgery and then started the heart was doomed to failure. The morbidity and mortality rates would be so great as to negate any possible positive results. In fact, the same dire consequences were predicted for cardiac catheterization. It took the conviction 00 scientists to catheterize each other and prove the safety of the procedure. Many years later, they were awarded the Nobel prize in medicine for this major accomplishment.
The revolution in heart surgery could not have occurred without significant advances in technology. As we approach the 21st century, cardiac surgery is now routine and interventions undreamed of are common, limited only by imagination and concepts. It is into this arena that the pathologist has been thrust, hopefully to survive, grow and keep pace with the clinicians. For the pathologist to be an equal partner in the cardiology environment, it is necessary to communicate effectively. The rapid expansion of technology from molecular biology to heart transplantation has required a new vocabulary and a review of the traditional approach to cardiac pathology. Cardiac biopsies, using the bioptome catheter, are now quite common and thousands have been performed. The ability to obtain several cardiac muscle biopsies at one time and to repeat the procedure in the same patient at future time intervals has thrown new light on the pathogenesis of disease states.
In the modern cardiology service, there are nu-WAGNER TOXICOLOGIC PATHOLOGY scaffoldingwhich supports myofibers and blood vessels. Of equal importance, collagen serves as lateral connections between cells and muscle bundles coordinating the delivery of force, generated by myocytes, to the ventricular chamber. Type I and III collagens by virtue of their tensile strengths and resilience are significant determinants ofdiastolic and systolic myocardial stiffness.It is this stiffnesswhich prevents myocardial deformation, maintaining geometric shape and wall thickness (28) . Recent studies (22) have demonstrated unique coiled perimysial fibers (CPF) coursing from the cardiac muscle-chorda tendinea junction, through the papillary muscle and into the wall of the rat heart. The potential tensile strength ofthe network ofCPF is sufficient to account for the mechanical properties of papillary muscle. CPFs look like springs, but whether this coiled configuration contributes significant elastic storage ofenergy is an open question. Cardiac function is the result of the interaction of cardiac muscle with the extracellular collagen components. It is important for the pathologist to recall that different types of collagen influence ventricular performance in distinct ways and their amount and distribution within the wall can lead to myocardial dysfunction. Mice with a genetic defect in the crosslinking of collagen show alterations in cardiac dynamics leading to abnormal pump function (3) .
The gross appearance ofthe heart and cut surfaces of the myocardium need to be assessed in terms of the clinical data. Appropriate sections are studied in a manner predetermined by the nature of the disease process. The pathologist must decide prior to the autopsy what structural studies are needed. These may range from routine and special stains, enzyme histochemistry and immunocytochemistry to electron microscopy.
ENDOGENOUS MODULATORS
Coronary artery constriction has been directly demonstrated in humans and animals. The epicardial arteries are now known to playa significant role in modulating coronary blood flow and are not just simple, passive conducting tubes to the intramyocardial branches (15) . Eicosanoids are important endogenous modulators of cardiac function (18) . The prostaglandins (PGs) act directly on the myocardium and the coronary vascular bed. Thromboxane (TX)A 2 is a potent coronary vasoconstrictor. During ischemia, eicosanoid production increases due to an increase in the release ofarachidonic acid from myocardial phospholipids. This may occur directly in a single catalytic step by the action of phospholipase A 2 or by a multistep sequential pathway initiated by phospholipase C and culminated by the sequential actions of di-and monoglyceride lipases.
In isolated coronary arteries, arachidonic acid leads to the synthesis of PGI 2 , PGE 2 , and TXA 2 • Although a vast literature exists, relatively little is known about myocardial eicosanoid release and synthesis, mechanisms and sites of action. Several studies suggest a direct cellular action ofPGs on the heart including alterations in glucose oxidation, myocardial O 2 consumption, myocardial triglyceride levels, cyclic (c)AMP levels and sarcolemmal Na", K+dependent ATPase activity. A recent report demonstrates that myocardial sarcolemmal vesicles contain high-affinity binding sites for PGE 2 • Coronary vessels are a major source of locally produced PGE 2 that may interact with receptors on the myocyte. In addition to humans, PGE 2 has marked effects on cardiac function in a number of species: rat, cat, dog, rabbit, and sheep.
There is a variety of drugs which affect the arachidonic acid cascade. Any assessment of cardiac tissue alterations must include the effects of therapeutic agents on myocardial and coronary artery function. Eicosanoids are important regulators of vascular smooth muscle contraction, hypertrophy and proliferation. As of this writing, there are 32 identified oxidation products resulting from arachidonic acid metabolism. These metabolites may play a role in recurrent vasoconstriction (9) .
Endothelin, a 21-amino acid peptide isolated from aortic endothelial cells in culture, is an extremely potent vasoconstrictor. Not only are coronary arteries constructed by endothelin but also strips or rings of rat aorta, cat basilar artery, rabbit and dog mesenteric arteries, and human mesenteric and pulmonary artery branches. Recently, the effects of endothelin on the coronary vascular bed in open-chest dogs have been reported (5) . Endothelin produced a dose-related coronary vasoconstriction larger in the subepicardium than in the subendocardium and a vasoconstriction of the large coronary arteries. The epicardial arteries can also be constricted by stimulation of o-adrenoreceptors, injection of serotonin, ergonovine, thromboxane or aggregated platelets. However, it appears that endothelin induced vasoconstriction is independent of these factors. Coronary vasospasm tends to occur in areas of arterial wall injury and endothelin secretion might be responsible (2) .
Endothelium-dependent vasorelaxation also occurs via endothelium-derived relaxation factor (EDRF) which is composed in part by nitric oxide (NO) (23) . The growing recognition of similar biological actions ofEDRF and NO has resulted in the demonstration of L-arginine as the likely precursor.
In the presence of oxygen, NO is highly unstable and is rapidly transformed to the free radicals N0 2and N0 3 -. Endothelium secretes EDRF which dif-fuses immediately to adjacent smooth muscle cells. NO is highly lipophilic and easily permeates plasma membranes.
Another endogenous coronary vasodilator is atrial natriuretic peptide (ANP). A synthetic 28-amino acid a-human ANP can induce marked sustained preferential proximal coronary dilations in humans. Because ANP shares certain vascular effects of nitrates, ANP may play an important role in the response to ischemia. Myocardial ischemia may lead to an increase in ventricular filling pressures and atrial pressures. The increase in atrial pressures stretches atrial myofibers increasing ANP release (25) . ANP reduces ischemia by dilation of the stenotic epicardial coronary arteries increasing total flow and distribution to subendocardium (4).
In the heart and in the walls of blood vessels, estradiol, dihydrotestosterone, corticosterone, aldosterone, dexamethasone and vitamin D show nuclear binding. There are data to indicate that all steroid hormones exert direct actions on the cardiovascular system at different levels of organization. The steroid hormones appear to act simultaneously but in different and varying capacities producing a broad range of cooperative or antagonistic actions (26) .
The pathologist has an opportunity to identify and localize some of these potent protein modulators of cardiac function. Immunocytochemical demonstration of endothelin, EDRF, and ANP can be accomplished in appropriate tissue sections. Steroid receptors may also be identified. These tissue assessments can assist in the interpretation of the functional abnormalities observed during life. Hearts perfused with fixative at appropriate pressures provide a more physiological view of the vascular bed. In my experience, sites of chronic, recurrent vasoconstriction usually show cuboidal to almost columnar type endothelial cells. Most striking is the maximally convoluted internal elastic membrane with focal splitting. The smooth muscle cells immediately adjacent to this membrane frequently show large, hyperchromatic nuclei with some distortion.
Vasoconstriction ofthe coronary vascular bed extends from the epicardial vessels to the arterioles. Extensions of smooth muscle cells are found in the precapillary area. One of the functions postulated for the basement membrane of smooth muscle cells is mechanical force transmission and maintenance of elastic properties. The smooth muscle cell is surrounded by basement membrane material on all sides which suggests that this structure may influence the access of effector molecules to the cell surface (10) . Also, the basement membrane may serve as a charge selective barrier due to its content of heparan sulphate. All ofthis postulates that smooth muscle cell basement membrane integrity is critical for the general metabolism and function of the cell. Basement membrane components, such as fibronectin, laminin and sulphated proteoglycans, can be visualized by immunocytochemical and histochemical methods. The presence of adrenergic nerves around arterioles and along capillaries may also facilitate vasoconstriction (6) .
MITRAL VALVE COMPLEX
The function of the mitral valve is dependent on the smooth functioning of four major components: annulus, leaflets, chordae tendinae and papillary muscles. If one of these components is abnormal, mitral valve function may be compromised. Chronic valvular dysfunction leads to structural changes in other components of the complex. Mitral regurgitation can occur in the absence of intrinsic abnormalities ofthe mitral leaflets (13) . It appears that functional sealing of the valve is accomplished by a sphincteric action of the annulus and a change in shape during systole. In addition, there are cardiac myofibers in the proximal leaflets which course through the mitral ring and may add to the stiffness of the leaflets at maximal systolic ejection. Functionally, these myofibers are different from left atrial myofibers in their response to pharmacologic agents and electrophysiology.
With the widespread use of cineangiographic and echocardiographic techniques, mitral valve prolapse (MVP) has emerged as a clinically important, common valvular abnormality (I). In most cases, it is the posterior mitral leaflet which is involved. The leaflet is a thin, membranous structure which encases connective tissue fibers, extracellular matrix and scattered mesenchymal cells. MVP appears to be inherited as an autosomal dominant phenotype. Biochemical studies of mitral valves obtained from patients with severe MVP and significant mitral regurgitation demonstrated collagen abnormalities. Many cardiologists classify familial MVP as one of the heritable connective tissue disorders. Because of ts high incidence in the general population, MVP IS the largest group ofpatients with connective tissue abnormality of the heart (I).
Patients with MVP and progressive mitral regurgitation usually have surgery with removal of the valve and prosthetic replacement. These surgical specimens tend to be large, "floppy," myxomatous mitral valves. About half of these specimens show ruptured or elongated chordae due to collagen dissolution or disruption. Myxomatous or "floppy mitral" valves is the most common etiologic diagnosis in patients having mitral surgery for pure mitral regurgitation in the US. These valves may be complicated by infectious endocarditis or embolic phe-WAGNER TOXICOLOGIC PATHOLOGY nomena. It is now clear that MVP includes a wide spectrum of valvular abnormalities. Therefore, it is of major clinical importance to avoid the overdiagnosis of MVP in normal individuals.
There appears to be a subpopulation of patients with the coexistence of symptoms that result from various forms of neuroendocrine or autonomic dysfunction. These symptoms cannot be explained on the basis of valvular pathology alone. Symptoms include chest pain, palpitations, fatigue, exercise intolerance, dyspnea, syncope and neuropsychiatric manifestations. Studies in these patients demonstrate a variety of neuroendocrine-autonomic dysfunctions. The pathogenesis of the symptoms appears to be multifactorial. Increased adrenergic activity, catecholamine regulation abnormality and adrenergic hyperresponsiveness may be noted. This syndrome has fascinated internists and cardiologists for more than 25 yr. The term MVP-syndrome has been proposed for this unique group of patients (I).
Amidst this clinical controversy, the pathologist can add substantial information. At autopsy, the mitral valve complex should be studied in detail. Attempts should be made to correlate gross and microscopic findings with functional studies. Since the MVP-syndrome symptoms cannot be explained on the basis of valvular pathology alone, attention of the pathologist should also be directed to the kidneys, adrenals and autonomic nervous system. Thus, MVP may be part of a neuroendocrine cardiovascular process which remains to be elucidated.
DILATED, CONGESTIVE CARDIOMYOPATHY AND THE FAILING HEART
The left ventricle in patients with dilated or congestive cardiomyopathy ofunknown etiology is more spherical than normal (16) . Contractile function, as determined from end-systolic stress-shortening and circumferential end systolic stress-dimension relations, is depressed. Although the heart weight may be increased 500-700 g (normal, 350 g), the thickness of the left ventricular wall is normal or thinner than normal. Mural thrombi may be present in all 4 dilated chambers. Grossly, the myocardium appears normal and histologically the myocardial changes are non-specific but significant. Cells range from hypertrophic to atrophic with varying amounts of intercellular fibrous tissue. In general, inflammatory cells are not present. Electron microscopy supports these light microscopic observations. Nonspecific EM findings include cellular edema, increased lipid droplets, lysosome and lipofuscin granules, myofibrillar damage and mitochondrial alterations. All of these changes may be associated with varying degrees of clinical failure (12, 16) .
One of the most important responses ofthe failing heart is myocardial hypertrophy (II). This adaptive process allows the heart to compensate for overloading. However, the cells of the hypertrophied, failing heart are not normal. Hypertrophy of the overloaded heart is a most complex process (30) . Sarcomeres are increased in number and this predominates at first, producing functional benefits. As the process becomes chronic, due to sustained overload, the detrimental effects of hypertrophy in chronic heart failure become apparent. Referred to as cardiomyopathy of overload (1) or congestive cardiomyopathy, it is the phase of end-stage heart disease.
In the hypertrophied heart, there is an increase in the distance between capillaries and a decrease in the density of transverse capillary profiles.This leads to impaired diffusion of cell substrates essential for the production of energy. Chronic hypertrophy increases the cell volume occupied by myofibrils requiring increased generation of ATP by mitochondria. Such energy demands tend to exacerbate an existing energy deficit. As contractility ofthe failing heart becomes depressed, energy demands may be decreased for the individual myocardial cells. While this may be a respite for the heart, depressed contractility is extremely serious for the circulation. This results in further under-perfusion of the subendocardial area with increasing cell degeneration, necrosis and fibroplasia (I, 27).
The failing heart is a changing structural and functional entity. Current research is attempting to elucidate those abnormalities which initiate and perpetuate the progressive deterioration of the hypertrophied, failing myocardium. Some interesting leads are emerging from molecular and cell biology. Abnormal gene expression has been detected in the hypertrophied myocardium. The heart has the ability to change its protein composition as a general process in adapting to functional demands. However, in the hypertrophic heart, abnormal isoforms of important myocardial proteins appear, resulting from altered gene expression. For example, the synthesis of myosin heavy chains is altered both in humans and animal models. Due to accelerated protein synthesis, fetal isoforms of several proteins occur. It appears that the adult myocardial cell reverts to a pattern of protein synthesis characteristic during development. Thus, the overloaded heart demonstrates a heterogeneity of protein isoforms as a result of abnormal synthesis (I, 11).
The areas of protein metabolism, abnormalities in the sarcoplasmic reticulum of the failing heart and the possible role of proto-oncogenes in activating and reprogramming gene expression in the overloaded heart are all suitable for investigation by pathologists. Although there remain many molecular and cellular changes in the hypertrophied heart which are poorly understood, they are involved in the initiation of long-term effects culminating in congestive cardiomyopathy. The application ofappropriate techniques for the study ofthe cardiac myofiber in the failing and failed heart will allow the pathologist to help in the elucidation of structure and function.
Endomyocardial transvenous or percutaneous biopsy is a well-established procedure. The bioptome can provide pieces of tissue ranging from 1-2 mm! and weighing up to 4 mg. Rapid fixation in 2% buffered glutaraldehyde (pH 7.35) in the cold for 4 hr and then transfer to phosphate buffer is a popular method. However, with multiple biopsies, 10% (V/ V) formaldehyde solution for routine histologic examination can be used, snap freezing (isopentane, liquid nitrogen) and frozen-tissue sections are also available. This permits a broad range ofstudies from hematoxylin and eosin stained slides, immunocytochemistry, histochemistry, electron microscopy, morphometry to chemical analysis.
The literature is beginning to reflect this functional, structural approach. In one study (27) ,a group ofinvestigators assessed the effectsoforal isosorbide dinitrate, hydralazine and the combination on myocardial cell size in patients with chronic, severe congestive heart failure associated with dilated, congestive cardiomyopathy. Vasodilator therapy is an accepted therapy in the treatment of congestive heart failure refractory to digitalis and diuretics. A treatment regimen using isosorbide dinitrate (a preload-reducing agent) or hydralazine (an afterloadreducing agent) or both is currently popular. From a functional standpoint, the combination therapy improves resting hemodynamic function. The tissue studies provided evidence that this functional improvement correlates with a decrease in myocardial cell size.
Hypertrophy regressed toward normal with beneficial effects for the patient by reducing intercapillary distance and increasing capillary density. It is not known whether these improvements lead to longterm benefits or decreased mortality. In another study (21) , biopsies were studied in 100 consecutive patients with idiopathic heart failure. The pathologic diagnostic information obtained was judged useful to the clinician in 54 patients. In 74 patients with cardiomyopathy of unknown etiology, useful pathologic diagnoses included myocarditis, vasculitis, doxorubicin and congestive cardiomyopathy. Of most interest was the finding that 19 of the 100 patients had myocarditis. These findings were confirmed by other investigators who also noted that inflammatory myocardial disease may be more common than previously suspected in many cases of congestive cardiomyopathy.
The role of inflammation in the development of dilated cardiomyopathy is not clear. There are reports suggesting that chronic, subclinical myocarditis can result in cardiac dilatation and failure (7, 29) . One of the problems for the pathologist evaluating endomyocardial biopsies is differentiating noninflammatory interstitial cells from lymphocytes. Misinterpretation of interstitial cells overestimates the degree of inflammation within the myocardium (21) . Immunocytochemical staining ofthese mononuclear cells reduces the chances of this error. Lymphocyte infiltration in normal myocardium is most unusual. T-lymphocyte infiltration is a hallmark of myocarditis and may be a major cause of tissue damage. The quantitation of T-lymphocytes by immunoperoxidase-stained sections appears to correlate with the clinical status of the patient (14) . This approach along with histologic analysis may produce quantitative, standardized criteria for the diagnosis and classification of myocarditis.
Two spontaneous animal models of cardiomyopathy have been studied extensively: Syrian hamster and the cat. The cardiomyopathic Syrian hamster is a reproducible and natural (genetically transmitted as an autosomal recessive) animal model of myocardial hypertrophy and failure. Animals younger than 40-50 days of age show little to no gross or light microscopic evidence of heart disease. They then enter the "necrotic" phase ofthe process, in which multiple focal areas of myocytolytic necrosis develop. All cardiac muscle layers and chambers are involved. The reparative process leads to fibrosis and calcification. Gradually, cardiac hypertrophy develops followed by chamber dilatation and failure. The animals either die suddenly or from congestive heart failure (24) . The Syrian hamster model shows increased cardiac sympathetic activity along with altered expression of sarcolemma calcium channels or of a!l receptors. Cardiac myocytes and vascular smooth muscle cells exhibit defective processing ofcalcium. Of interest, there is increased expression of the c-myc oncogene in cardiac myocytes before overt heart disease is detected. The disease becomes apparent with the onset of microvascular spasm, reperfusion injury and loss ofmyocytes. Verapamil or prazosin have been shown to effectively prevent the disease if administered to juvenile hamsters.
Feline congestive cardiomyopathy (17) is a spontaneous disorder noted primarily in Siamese, Abyssinian and Burmese breeds. It is usually seen in middle-aged cats and there is an equal sex distribution. Gross examination reveals a markedly enlarged and globular-shaped heart. There is severe attenuation of the papillary muscles. The mitral complex is commonly involved: shortened, thickened leaflets;altered thickness and length ofchordae and an upward malposition ofthe papillary muscles. There may be concomitant changes in the tricuspid valve complex. By light and electron microscopy, the histopathology is strikingly similar to human dilated, congestive cardiomyopathy. Although the etiology is not fully understood, congenital malformations of the mitral and/or tricuspid valve complexes appear to be causal.
While the Syrian hamster and feline models of congestive cardiomyopathy share some similarities with the human disease, there are important differences. Nevertheless, these models offer an unusual opportunity to study the structure and function of cardiac muscle cells in pathologic states. Calcium channel inhibitors have been used to treat human congestive cardiomyopathy. The animal models provide a temporal framework in which to explore the natural history of the disease. Drug discovery programs using these models must be aware of the limitations in making generalizations for humans. SUMMARY As a student of cardiovascular pathology in humans and animals for 35 yr, I am impressed with the new knowledge of the molecular biology, biochemistry, physiologyand pharmacology of the heart in health and disease. All of this information creates a dynamic setting for the interpretation of structural findings. Before the advent of open-heart surgery and the cardiac biopsy, pathologists had to rely largely on accumulated autopsy data. Today, a great deal of empiric dogma has given way to good science. In 1962, I met Professor FZ Meerson in his laboratory in the Institute of Normal and Abnormal Physiology, Moscow. He had just characterized the biochemical events leading to myocardial degeneration and cell death in animals with acute aortic constriction (19) . His pioneering work provided the basis for understanding the sequential changes in myocytes in the failing heart. These cellular events corresponded to the astute clinical observations made by Osler in 1886.
Meerson was enthusiastic about the potential of electron microscopy. However, he was convinced that when we had the techniques to identify and localize in the cardiac muscle cell the key chemical entities associated with changing function, we would rapidly understand pathogenesis leading to new therapies. Today, almost 30 yr later, Meerson's prophetic insights have become a reality. I had assured Meerson that when the tools were available to study the dynamic pathology of the heart, pathologists would lead the way.
Dynamic pathology ofthe heart is a concept since the words are somewhat contradictory. The term serves as a symbol for a state of mind which refuses to interpret cardiovascular pathology in static, histologic words. Rather, the detailed functional observations made during life become essential for interpretation of tissue changes. For this, the pathologist has a rich armamentarium of skills with new ones being added constantly. As we approach the 21st century, the pathologist is an equal member of the clinical cardiovascular team.
